First human test for potential Long-Lasting bleeding disorder treatment
NCT ID NCT04770935
Summary
This early-stage study tested a single injection of an experimental drug called BIVV001 in six adults with severe forms of von Willebrand disease (VWD), a bleeding disorder. The main goals were to see how long the drug stays active in the body and to check for any safety issues. This was a first step to see if the treatment could potentially help control bleeding episodes for longer periods.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND'S DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hemophilia Center of Western Pennsylvania_Investigational Site Number :8400001
Pittsburgh, Pennsylvania, 15213, United States
-
Investigational Site Number :2500001
Lille, 59037, France
-
Investigational Site Number :2500002
Nantes, 44093, France
-
University of Iowa_Investigational Site Number :8400002
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.